Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$12.63 - $24.47 $4.73 Million - $9.16 Million
-374,209 Reduced 33.28%
750,250 $17.7 Billion
Q3 2023

Nov 14, 2023

SELL
$10.86 - $17.62 $687,894 - $1.12 Million
-63,342 Reduced 5.33%
1,124,459 $16.8 Billion
Q2 2023

Aug 14, 2023

SELL
$7.47 - $10.95 $3.3 Million - $4.84 Million
-441,663 Reduced 27.1%
1,187,801 $13 Billion
Q1 2023

May 15, 2023

BUY
$5.88 - $9.59 $103,993 - $169,608
17,686 Added 1.1%
1,629,464 $14.2 Billion
Q4 2022

Feb 09, 2023

BUY
$3.22 - $6.27 $5.19 Million - $10.1 Million
1,611,778 New
1,611,778 $5.72 Billion

Others Institutions Holding CBAY

About CymaBay Therapeutics, Inc.


  • Ticker CBAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,677,904
  • Description
  • CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...
More about CBAY
Track This Portfolio

Track Saturn V Capital Management LLC Portfolio

Follow Saturn V Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Saturn V Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Saturn V Capital Management LLC with notifications on news.